PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching. (2023)
Attributed to:
MICA: Using circulating tumour DNA to identify and predict mechanisms of resistance to targeted cancer therapies.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41571-022-00712-3
PubMed Identifier: 36424404
Publication URI: http://europepmc.org/abstract/MED/36424404
Type: Journal Article/Review
Volume: 20
Parent Publication: Nature reviews. Clinical oncology
Issue: 2
ISSN: 1759-4774